SCHEMBL16184378

SCHEMBL16184378

CNc1nc(-c2cnccn2)nc2c(F)cc(-c3cc(F)cc(Cl)c3)cc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 2/20 0.35
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ MAT2A P31153 1/20 0.34
▸ PKM P14618 1/20 0.33
▸ MAP4K4 O95819 2/20 0.32
▸ LATS1 O95835 1/20 0.32
▸ LATS2 Q9NRM7 1/20 0.32
▸ LIMK1 P53667 5/20 0.32
▸ LIMK2 P53671 5/20 0.32
▸ LRRK2 Q5S007 1/20 0.32
▸ METAP2 P50579 1/20 0.31
▸ METAP1 P53582 1/20 0.31
▸ SCN9A Q15858 2/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184368 0.92 GRM5 (0.38) GRM5NPC1RAB9AMAT2AMAP4K4
SCHEMBL16184369 0.88 NPC1 (0.44) NPC1RAB9AMAT2APKMMAP4K4
SCHEMBL16184370 0.88 MAP4K4 (0.45) GRM5NPC1RAB9AMAT2APKM
SCHEMBL16184364 0.87 LATS1 (0.37) GRM5NPC1RAB9APKMLATS1
SCHEMBL16184384 0.86 NPC1 (0.37) NPC1RAB9AMAT2APKMMAP4K4
SCHEMBL16184371 0.86 CYP17A1 (0.36) NPC1RAB9AMAT2APKMLATS1
SCHEMBL16184373 0.85 NPC1 (0.36) NPC1RAB9AMAT2APKMMAP4K4
SCHEMBL16184361 0.85 MAP4K4 (0.42) GRM5NPC1RAB9AMAP4K4LATS1
SCHEMBL16184375 0.84 TGFBR1 (0.41) NPC1RAB9AMAT2APKMLATS1
SCHEMBL16184382 0.83 MAT2A (0.39) NPC1RAB9AMAT2APKMLATS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB GRM5 37/4885NPC1 2208/4885RAB9A 1340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback